NY-UPTIME-INSTITUTE
Uptime Institute today announced the release of its 14th Annual Global Data Center survey. The increased demand for digital services with both volume and compute intensity is challenging the power and cooling capabilities of much of the existing infrastructure. To meet the rising demand, data center operators and their IT clients are both investing and innovating more in their IT services and facilities and using external services. The effectiveness and impact of these investments will serve to shape the industry in the years ahead.
“Our data shows operators poised for major changes ahead on multiple levels,” said Andy Lawrence, executive director of research, Uptime Intelligence. “In 2024, we see the challenges of increased demand impacting power and cooling capabilities of existing facilities and the need for further investment to keep up with the demand. At the same time the industry needs to focus on continued staffing challenges to match capacity growth. And regulatory requirements are here and cannot be dismissed.”
Now in its 14th year, Uptime Institute’s annual survey remains the most comprehensive and longest-running study of its kind. The findings of this report highlight the practices and experiences of data center owners and operators in the areas of resiliency, sustainability, efficiency, staffing, cloud and artificial intelligence. It provides detailed insights into the digital infrastructure landscape and a view into its future trajectory. Key findings from the 2024 report include:
- Fewer than one half of data center owners and operators are tracking the metrics needed to assess their sustainability and/or meet pending regulatory requirements.
- Most operators recognize the benefits of AI and its potential. But despite many operators planning to host the technology, trust in AI for use in data center operations has declined for the third year in a row.
- The frequency and severity of data center outages remain mainly unchanged from 2023 or show small improvements. Operators are countering increases in complexity, density and extreme weather with investment and good management practices.
- Average server rack densities are increasing but remain below 8 kilowatts (kW). Most facilities do not have racks above 30kW, and those that do have only a few. This is expected to change in coming years.
- Enterprises continue to meet their IT needs with hybrid architectures. More than one half of workloads (45%) are now off-premises, continuing the gradual trend of recent years. Many continued to maintain their own data centers.
- Staffing challenges have neither improved nor worsened from 2023. More effort is needed to expand labor pools and skillsets to match the pace of capacity growth.
- Average PUE levels remain mostly flat for the fifth consecutive year, but this conceals advances in newer, larger facilities.
About the Survey:
Uptime conducted this year’s annual Global Data Center Survey online and by email in the first half of 2024. The survey participants represent a wide range of industry verticals in multiple countries. Responses were collected from a total of 879 end users registered for the survey and answered at least one question. More than one half are located in North America and Europe. Approximately one third of respondents work for professional IT/data center service providers (staff with operational or executive responsibilities for a third-party data center), such as those offering colocation, wholesale, software or cloud computing services.
Learn More:
Download the executive summary report here and register for the webinar here covering key trends and takeaways from the survey results on July 31st at 9:00 AM PDT (9:00 AM PDT, 12:00 PM EDT, and 5:00 PM BST). To join our Uptime Institute Bright Talk Channel, go to https://www.brighttalk.com/join/.
About Uptime Institute
Uptime Institute is the Global Digital Infrastructure Authority. With over 3,500 awards issued in over 118 countries around the globe, and over 1,000 currently active projects in 80+ countries, Uptime has helped tens of thousands of companies optimize critical IT assets while managing costs, resources, and efficiency.
For over 30 years, the company has established industry-leading benchmarks for data center performance, resilience, sustainability, and efficiency, which provide customers assurance that their digital infrastructure can perform across a wide array of operating conditions at a level consistent with their individual business needs. Uptime’s Tier Standard is the IT industry’s most trusted and adopted global standard for the design, construction, and operation of data centers. Offerings include the organization’s Tier Standard and Certifications, Management & Operations reviews and assessments including SCIRA-FSI financial sector risk assessment, the Sustainability Assessment and a broad range of additional risk management, performance, availability, and related offerings. Uptime Education training programs have been successfully completed by over 90,000 data center professionals, expanded by the acquisition of CNet Training, Ltd.
Uptime Institute is headquartered in New York, NY, with main offices in London, Sao Paulo, Dubai, Riyadh, Singapore, and Taipei, and full-time Uptime professionals based in over 34 countries around the world. For more information, please visit uptimeinstitute.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240730874079/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release
Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
